Key Takeaways for Executives and Industry Leaders
- Strategic AI Integration: Tempus and Boehringer Ingelheim launch a long-term partnership to integrate AI and real-world data into cancer drug development.
- Enhanced Oncology R&D: Boehringer gains access to Tempus’ multimodal patient database and the Lens platform to refine biomarker discovery and treatment strategies.
- Accelerated Innovation Cycle: The collaboration aims to shorten timelines for target discovery and treatment personalization across hard-to-treat cancers.
Tempus expands AI reach with a leading pharma partner
Tempus AI, a frontrunner in precision medicine and AI-driven clinical solutions, has solidified a strategic, multi-year collaboration with Boehringer Ingelheim, a major global player in oncology innovation. This marks a significant expansion of their ongoing partnership and represents a strong validation of Tempus’ capabilities in leveraging AI, real-world data (RWD), and multimodal analytics to drive actionable insights in oncology.
Boehringer Ingelheim taps multimodal data to unlock novel cancer therapies
Boehringer Ingelheim will access Tempus’ de-identified database of molecular, clinical, and imaging data, along with its proprietary Lens platform. This will enable Boehringer’s teams to:
- Conduct deeper biomarker exploration
- Stratify patient cohorts more effectively
- Develop hypothesis-driven drug combinations
- Map real-world patient journeys to uncover unmet needs
This collaboration directly supports Boehringer’s mission to target hard-to-treat cancers with smarter, more personalized therapeutics.
AI-powered insights to transform oncology R&D pipelines
The partnership is designed to accelerate Boehringer’s oncology pipeline by combining Tempus’ AI-enabled RWD analytics with Boehringer’s preclinical experimental data. Together, the companies aim to unlock the complexities of cancer biology and optimize therapeutic development by enhancing precision, predicting efficacy earlier, and reducing development risks.
Driving faster, smarter drug discovery for hard-to-treat cancers
With the increasing complexity of oncology therapeutics, AI integration is no longer optional—it’s foundational. This alliance demonstrates how combining clinical insights, advanced analytics, and real-world evidence can reshape how cancer treatments are discovered, evaluated, and brought to patients. As Boehringer Ingelheim aims to build a next-generation oncology pipeline, Tempus’ data-driven platform may be a crucial differentiator.
By